These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15150548)

  • 21. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
    Rosenberg JE; Ryan CJ; Weinberg VK; Smith DC; Hussain M; Beer TM; Ryan CW; Mathew P; Pagliaro LC; Harzstark AL; Sharib J; Small EJ
    J Clin Oncol; 2009 Jun; 27(17):2772-8. PubMed ID: 19349545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
    Berthold DR; Pond GR; Roessner M; de Wit R; Eisenberger M; Tannock AI;
    Clin Cancer Res; 2008 May; 14(9):2763-7. PubMed ID: 18451243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
    Collins R; Trowman R; Norman G; Light K; Birtle A; Fenwick E; Palmer S; Riemsma R
    Br J Cancer; 2006 Aug; 95(4):457-62. PubMed ID: 16880788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer.
    Galli L; Fontana A; Galli C; Landi L; Fontana E; Antonuzzo A; Andreuccetti M; Aitini E; Barbieri R; Di Marsico R; Falcone A
    Br J Cancer; 2007 Dec; 97(12):1613-7. PubMed ID: 18026196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy of prostate cancer: present and future.
    Trump D; Lau YK
    Curr Urol Rep; 2003 Jun; 4(3):229-32. PubMed ID: 12756087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.
    Eisenberger MA; Antonarakis ES
    Urol Clin North Am; 2012 Nov; 39(4):573-81. PubMed ID: 23084532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
    Petrylak D
    BJU Int; 2005 Dec; 96 Suppl 2():41-6. PubMed ID: 16359438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.
    Nakabayashi M; Ling J; Xie W; Regan MM; Oh WK
    Cancer J; 2007; 13(2):125-9. PubMed ID: 17476141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
    Van Poppel H
    Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
    Petrylak DP
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002.
    DeGrendele H
    Clin Prostate Cancer; 2003 Mar; 1(4):212-4. PubMed ID: 15040878
    [No Abstract]   [Full Text] [Related]  

  • 32. [Prostate cancer: future strategies for chemotherapy management].
    Fizazi K
    Ann Urol (Paris); 2007 Oct; 41 Suppl 3():S77-9. PubMed ID: 18297905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
    Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW
    Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy for hormone-refractory prostate cancer.
    Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The current role of chemotherapy in metastatic hormone-refractory prostate cancer.
    Petrylak DP
    Urology; 2005 May; 65(5 Suppl):3-7; discussion 7-8. PubMed ID: 15885271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What next after hormonotherapy in cancer prostate?
    Parvez T; Al-sisi H; Ibraheim I
    J Coll Physicians Surg Pak; 2003 Oct; 13(10):606-10. PubMed ID: 14588180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Docetaxel in hormone-refractory metastatic prostate cancer.
    McKeage K; Keam SJ
    Drugs; 2005; 65(16):2287-94; discussion 2295-7. PubMed ID: 16266195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current indications for chemotherapy in prostate cancer patients.
    Calabrò F; Sternberg CN
    Eur Urol; 2007 Jan; 51(1):17-26. PubMed ID: 17007996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis.
    Song P; Huang C; Wang Y
    Int J Surg; 2018 Aug; 56():133-140. PubMed ID: 29906643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy for androgen-independent prostate cancer.
    Petrylak DP
    Semin Urol Oncol; 2002 Aug; 20(3 Suppl 1):31-5. PubMed ID: 12198636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.